Related Experiment Video
Updated: Aug 12, 2026
Optimized Protocols for Mycobacterium leprae Strain Management: Frozen Stock Preservation and Maintenance in Athymic Nude Mice
Published on: March 23, 2014
Effect of various microbial preparations on P-388 mouse lymphocytic leukemia
M D Antoun1, R Caballero, I Robledo
1Department of Pharmaceutical Sciences, School of Pharmacy, UPR, San Juan 00936-5067.
Abstract:
Four bacteria-derived immunopotentiators were tested for their protective effect on a P-388 mouse lymphocytic leukemia model. The microbial test products were prepared from the following bacterial strains: ATCC 35983 Staphylococcus epidermidis isolated from a patient with IV catheter; ATCC 31874, a patented strain listed as Staphylococcus epidermidis isolated from the urine of a cancer patient; ATCC 25615 Staphylococcus hominis obtained from a child with lymphocytic leukemia, and ATCC 25614 Staphylococcus warneri, an isolate from a patient with adenocarcinoma of the breast. A limited degree of protection and prolongation in survival time was observed in the animal group treated with the bacterial strain ATCC 31874.
Insights
This study investigated bacteria-derived immunopotentiators against lymphocytic leukemia in mice. One Staphylococcus epidermidis strain, ATCC 31874, showed limited protective effects and prolonged survival time in the P-388 mouse model.
Area of Science:
- Immunology
- Microbiology
- Oncology
Background:
- Bacterial components are explored for immunomodulatory and anti-cancer properties.
- The P-388 mouse lymphocytic leukemia model is a standard for evaluating anti-leukemic agents.
- Staphylococcus species are known sources of bioactive compounds.
Purpose of the Study:
- To evaluate the protective effects of four bacteria-derived immunopotentiators against P-388 mouse lymphocytic leukemia.
- To determine if specific bacterial strains can enhance survival time in a leukemia mouse model.
Main Methods:
- Four bacterial strains (Staphylococcus epidermidis ATCC 35983, Staphylococcus epidermidis ATCC 31874, Staphylococcus hominis ATCC 25615, Staphylococcus warneri ATCC 25614) were used to prepare microbial test products.
- These products were administered to mice with P-388 lymphocytic leukemia.
- Survival time and protective effects were assessed in the treated animal groups.
Main Results:
- A limited degree of protection was observed in the P-388 mouse lymphocytic leukemia model.
- Treatment with the bacterial strain ATCC 31874 (Staphylococcus epidermidis) resulted in a prolongation of survival time.
- Other tested bacterial strains did not show significant protective effects.
Conclusions:
- The bacterial strain ATCC 31874, a Staphylococcus epidermidis isolate, demonstrated modest immunopotentiating and anti-leukemic activity in the P-388 mouse model.
- Further research into bacterial immunomodulators may yield novel therapeutic strategies for leukemia.
- Specific bacterial strains hold potential as sources for anti-cancer agents.
